Table 3 Clinical trials on macrophage polarization and inflammation
From: The role of macrophage subtypes and exosomes in immunomodulation
Status | Study title | Intervention | ClinicalTrials.gov identifier |
|---|---|---|---|
Recruiting | Treatment of macrophage activation syndrome (MAS) with anakinra | •Drug: kineret •Drug: placebo | NCT02780583 |
Completed | Effect of liraglutide (Victoza) on inflammation in human adipose tissue and blood | •Drug: Victoza (liraglutide) with dietician monitoring •Other: placebo with dietician monitoring | NCT02650206 |
Completed | The effect of gut sterilization on macrophage activation in patients with alcoholic hepatitis | •Drug: combined vancomycin and gentamycin and meropenem | NCT03157388 |
Completed | Macrophage activation markers during sofosbuvir-based treatment regimens of chronic hepatitis C | •Drug: galactose •Procedure: gastroscopy •Procedure: liver biopsy •Procedure: FibroScan •Procedure: liver vein catheterization •Drug: sofosbuvir | NCT02528461 |
Unknown status | New candidate criteria for diagnosis of macrophage activation syndrome | – | NCT01095146 |
Completed | Exploration of immunity in Gaucher disease | – | NCT01358188 |
Completed | A study to investigate the safety and efficacy of emapalumab, an anti-IFN-gamma mAb in patients with systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still’s disease (AOSD) developing macrophage activation syndrome/secondary HLH (MAS/sHLH) | •Drug: emapalumab | NCT03311854 |
Recruiting | sCD163 in patients with PBC—assessment of disease severity and prognosis | •Other: blood samples, FibroScan, and questionnaires | NCT02924701 |
Completed | A role for RAGE/TXNIP/inflammasome axis in alveolar macrophage activation during ARDS (RIAMA): a proof-of concept clinical study | •Other: RAGE/TXNIP/inflammasome axis | NCT02545621 |
Recruiting | sCD163 in patients with PBC—assessment of treatment response | •Other: blood samples •Device: FibroScan •Other: questionnaires •Biological: liver biopsy | NCT02931513 |
Completed | Downmodulating monocyte activation for HIV-1-associated neurocognitive disorders (HAND) | •Drug: atorvastatin (Lipitor) •Drug: placebo | NCT01600170 |
Completed | A trial of validation and restoration of immune dysfunction in severe infections and sepsis | •Drug: anakinra •Drug: recombinant human interferon gamma •Drug: placebo | NCT03332225 |